Across TCGA pan-cancer cohorts, PRTN3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRTN3 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PRTN3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRTN3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where PRTN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.393	0.726	.010	29	view →
LUAD	OS	Tertile	III,IV	0.216	0.743	.003	12	view →
HNSC	DFS	Tertile	III,IV	0.911	1.000	.042	2	view →
PDAC	DFS	Quartile	III,IV	0.651	0.236	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PRTN3 tumor-vs-normal RNA expression · all PRTN3 data types